Case Report: Two Cases Of Partial Response to Anti-EGFR Antibody-drug Conjugate Plus PD-1 Blockade in Advanced Penile Squamous Cell Carcinoma

Background Advanced penile squamous cell carcinoma (PSCC) is a rare malignancy with limited effective systemic treatment options. The development of new treatment strategies is therefore particularly important in this setting. Case presentation We report two cases diagnosed with advanced PSCC and bilateral inguinal lymph node metastases. The tumor was EGFR-positive, HPV-negative, and had a PD-L1 tumor proportion score of 1%, a TP53 p.Q317* mutation, low tumor mutational burden, and microsatellite-stable status. After thorough and extensive communication, the patients and their families agreed to assume the risks and requested first-line therapy with an anti-EGFR ADC (Becotatug Vedotin) plus a PD-1 inhibitor (Pucotenlimab). After treatment, the patients achieved a partial response according to RECIST v1.1, accompanied by marked clinical regression of the inguinal lesion. Treatment-related adverse events were limited to manageable grade 1 decreased appetite, rash, fatigue, and hepatic dysfunction. Conclusions These cases suggest that anti-EGFR ADC plus PD-1 inhibition may represent a feasible and biologically rational first-line treatment option for advanced PSCC. Further prospective evaluation of this strategy is warranted.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11268602/v1
Primary Topic
Genital Health and Disease
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Case Report: Two Cases Of Partial Response to Anti-EGFR Antibody-drug Conjugate Plus PD-1 Blockade in Advanced Penile Squamous Cell Carcinoma

Jiayao Wang, Hongshuai Li, Ruizhi Liu, Jiaqi Liu et al.
4 links
Research Square
Genital Health and Disease
preprint

Case Report: Two Cases Of Partial Response to Anti-EGFR Antibody-drug Conjugate Plus PD-1 Blockade in Advanced Penile Squamous Cell Carcinoma

Jiayao Wang, Hongshuai Li, Ruizhi Liu, Jiaqi Liu, Mingyi Zhang, Ji-Yan Liu, Li-Li Yang, Shuang Zhang
preprint en

Abstract

Background Advanced penile squamous cell carcinoma (PSCC) is a rare malignancy with limited effective systemic treatment options. The development of new treatment strategies is therefore particularly important in this setting. Case presentation We report two cases diagnosed with advanced PSCC and bilateral inguinal lymph node metastases. The tumor was EGFR-positive, HPV-negative, and had a PD-L1 tumor proportion score of 1%, a TP53 p.Q317* mutation, low tumor mutational burden, and microsatellite-stable status. After thorough and extensive communication, the patients and their families agreed to assume the risks and requested first-line therapy with an anti-EGFR ADC (Becotatug Vedotin) plus a PD-1 inhibitor (Pucotenlimab). After treatment, the patients achieved a partial response according to RECIST v1.1, accompanied by marked clinical regression of the inguinal lesion. Treatment-related adverse events were limited to manageable grade 1 decreased appetite, rash, fatigue, and hepatic dysfunction. Conclusions These cases suggest that anti-EGFR ADC plus PD-1 inhibition may represent a feasible and biologically rational first-line treatment option for advanced PSCC. Further prospective evaluation of this strategy is warranted.

Research Square
West China Hospital of Sichuan University (CN)
Good health and well-being
Genital Health and Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon